Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Recent progress in the management of pediatric chronic myeloid leukemia - Review (Shima H. and Shimada H. Int J Hematol, February 2023)

Recent progress in the management of pediatric chronic myeloid leukemia
Shima H & Shimada H. Int J Hematol, February 2023 – open access publication

 

 

 

Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations - Review (Sembill S et al. Leukemia, January 2023)

Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations – Review
Sembill S et al. Leukemia, January 2023 (epub ahead of print) – open access publication

 

 

 

Children with chronic myeloid leukemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicentre experience in Taiwan (Liu HC et al. Br J Cancer, January 2023)

Children with chronic myeloid leukemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults:
a multicenter experience in Taiwan
Liu HC et al. Br J Cancer, January 2023 (epub ahead of print)

 

 

 

Impact of tyrosine kinase inhibitors applied for first-line chronic myeloid leukemia treatment on platelet function in whole blood of healthy volunteers in vitro (Eckart F et al. Hamostaseologie, January 2023)

Impact of tyrosine kinase inhibitors applied for first-line chronic myeloid leukemia treatment on platelet function in whole blood of healthy volunteers in vitro
Eckart F et al. Hamostaseologie, January 2023 (epub ahead of print)

 

 

 

Relative bioavailability and food effect of asciminib pediatric mini-tablet formulation compared to the reference tablet formulation in healthy adult participants (Hoch M et al. Clin Pharmacol Drug Dev, January 2023)

Relative bioavailability and food effect of asciminib pediatric mini-tablet formulation compared to the reference tablet formulation in healthy adult participants
Hoch M et al. Clin Pharmacol Drug Dev, January 2023 (epub ahead of print) – open access publication

 

 

 

  1. Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia (Schleicher O et al. Front Oncol, September 2022)
  2. Recent progress in the management of pediatric chronic myeloid leukemia - Review (Shima H. and Shimada H. Int J Hematol, December 2022)
  3. Alterations in cellular metabolism after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review (Li C et al. Front Oncol, December 2022)
  4. Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors (Nishiyam-Fujita Y et al. Ann Med, December 2022)